Market Overview

UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

Share:
Related BMRN
Short Sellers Dump Vertex, Load Up On Baxalta
BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide
Biogen Spinning Off Hemophilia Business As Competition Heats Up (Investor's Business Daily)

Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Hold to Buy and announced a $67.00 price target.

Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701 expansion cohort data remains limited, we believe the pipeline provides multiple additional sources of optionality to drive upside in FY13. We believe the company represents an attractive acquisition candidate near-term while also being one of the few (if any) names that seemingly has a sustainable pathway in place to independently achieve large-cap status longer-term."

BioMarin Pharmaceutical closed at $54.08 on Friday.

Latest Ratings for BMRN

DateFirmActionFromTo
Apr 2016JefferiesMaintainsBuy
Apr 2016BMO CapitalInitiates Coverage onOutperform
Mar 2016Credit SuisseMaintainsOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!